What Tissue Dynamics does

Tissue Dynamics is a private Israeli biotechnology company founded in 2017 and headquartered in Rehovot, Israel, with a European office in Paris. The company builds an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors and high-throughput robotic automation to generate human-relevant preclinical data for drug discovery and toxicity assessment, primarily serving pharmaceutical and biotechnology research teams.

The company's core offering is the Bionic Discovery Platform, which integrates three proprietary technology layers: DynamiX, a sensor platform providing real-time readout of organoid metabolism and function under physiological conditions; MechaniX, an AI software suite that reconstructs metabolic networks and process dynamics, identifies novel targets, and claims to predict human-relevant toxicity with over 95% accuracy; and a robotic automation platform that forms, tracks, and studies over 20,000 human organoids in parallel. Complementing the platform are four service lines — Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology — delivered through custom-engagement, project-based contracts. Scientific credibility is supported by publications in Nature, eLife, and Science Translational Medicine, and the team includes Nobel laureate Roger Kornberg (Stanford) and former TEVA CEO Erez Vigodman as advisors.

Tissue Dynamics operates a B2B professional services model, generating revenue through collaborative drug development partnerships, custom assay development, compound screening, and safety/toxicology engagements with pharma and biotech clients. Pricing is not publicly disclosed and is structured as bespoke project quotes rather than standardized list pricing. The go-to-market relies on scientific publications, peer-reviewed case studies, and direct scientific-team engagement rather than traditional sales channels, targeting enterprise R&D buyers. The company's only named strategic partnership is with Galmed Pharmaceuticals (announced 2026-05-06) for a cardiac fibrosis program combining Aramchol-based therapeutics with the organoid platform.

Name

Tissue Dynamics

Legal name

Tissue Dynamics

Website

https://tissuedynamics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Tissue Dynamics is a private Israeli biotechnology company that builds an AI-powered organ-on-a-chip platform combining human organoids, embedded metabolic sensors, and high-throughput robotic automation to deliver human-relevant drug discovery and toxicology screening services to pharmaceutical and biotech R&D teams.

Ownership category

akta.pro rank

Product category

Preclinical Drug Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Organ-on-chip platform
• Drug toxicity screening
• Human organoid models
• Preclinical drug testing
• AI drug discovery

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Development Services: Revenue generated through service contracts including compound profiling and screening, model and assay development, safety pharmacology and toxicology assessment, and collaborative drug development partnerships. Services are offered to pharmaceutical and biotech companies seeking human-relevant drug discovery data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Tissue Dynamics develops and operates an AI-powered organ-on-a-chip platform that combines human organoids with embedded metabolic sensors, robotic automation, and AI analysis to deliver human-relevant drug toxicity, efficacy, and mechanism-of-action data. The company sells preclinical drug development services to pharmaceutical and biotechnology companies, including compound profiling, custom assay development, safety pharmacology/toxicology assessment, and collaborative drug development partnerships.

Product overview

Tissue Dynamics offers a unified Bionic Discovery Platform combining DynamiX (real-time metabolic sensor technology), MechaniX (AI-powered metabolic network reconstruction software), and high-throughput robotic automation capable of studying over 20,000 human organoids in parallel. The platform is complemented by four service offerings: Compound Profiling & Screening, Model & Assay Development, Drug Development Partnerships, and Safety Pharmacology & Toxicology. The DynamiX platform provides real-time metabolic readouts while MechaniX employs AI to reconstruct metabolic networks and predict human-relevant toxicity with over 95% accuracy.

Differentiator

Problem solved

Functional benefit

Products and services

• Bionic Discovery Platform Massively scalable organ-on-a-chip platform combining embedded metabolic sensors, AI analysis, and high-throughput robotic automation for human-relevant drug discovery and toxicity prediction, sold to pharmaceutical and biotechnology companies.
• DynamiX Advanced sensor technology platform enabling real-time readout of human organoid metabolism and function under physiological conditions, providing critical insight into disease dynamics and mechanisms for drug discovery researchers.
• MechaniX AI-powered software suite that reconstructs metabolic networks and process dynamics to identify novel drug targets, generate unique therapeutic assets, and predict human-relevant toxicity with over 95% accuracy.
• Compound Profiling & Screening Real-time human organoid screening service delivering unmatched functional and metabolic insights to support smarter drug development decisions for pharmaceutical and biotech clients.
• Model & Assay Development Custom design of organoid models with integrated biomarkers and multi-omics endpoints, providing precise mechanism-of-action and translational insights for pharmaceutical and biotech researchers.
• Drug Development Partnerships Collaborative service integrating human disease biology with the Tissue Dynamics scientific team to accelerate candidate validation and translation toward clinical success for pharmaceutical and biotech partners.
• Safety Pharmacology & Toxicology Organoid-based toxicology assessment across key human tissues, tracking tissue injury and off-target effects with continuous readouts, designed for pharmaceutical and biotech safety evaluation.

Quantifiable outcome

• Fourfold reduction in fibrotic burden while maintaining cardiac function in preclinical cardiac fibrosis studies
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• Galmed PharmaceuticalscoreStrategic or Co-development Partner · 6 May 2026Strategic collaboration to develop a novel human chronic cardiac fibrosis platform using vascularized, sensor-embedded cardiac organoids to advance Aramchol-based therapeutics for conditions including post-myocardial infarction remodeling and HFpEF. The partnership combines Tissue Dynamics' high-throughput organoid technology with Galmed's expertise in SCD1 biology and metabolic pathway modulation.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Emulate: Emulate is a direct organ-on-chip competitor offering its Organ-Chip platform for human-relevant disease modeling and drug toxicity testing. Both companies target pharma R&D with microphysiological systems designed to replace animal models.
• Mimetas: Mimetas develops OrganoPlate-based organoid and organ-on-chip models for high-throughput drug screening. It directly competes with Tissue Dynamics in providing human-relevant preclinical disease models to pharmaceutical partners.
• CN Bio Innovations: CN Bio develops multi-organ microphysiological systems (e.g., PhysioMimix) for drug safety and efficacy testing. It competes head-to-head with Tissue Dynamics in organ-on-chip services aimed at pharma toxicology and disease modeling.
• TissUse: TissUse builds multi-organ-on-chip platforms (MOC) for systemic toxicity and efficacy testing. It is a direct competitor serving similar pharma clients with chip-based human model screening services.
• InSphero: InSphero provides 3D microtissue and organoid models for toxicology and disease research. It overlaps with Tissue Dynamics in human organoid-based drug discovery platforms sold to pharmaceutical R&D.

Emerging players

• Hesperos: Hesperos builds multi-organ human-on-a-chip systems used in preclinical drug testing. It overlaps with Tissue Dynamics in human-relevant physiology platforms but focuses on integrated multi-organ configurations rather than high-throughput organoid scaling.
• DefiniGEN: DefiniGEN provides iPSC-derived disease models and organoid services for drug discovery. It is comparable to Tissue Dynamics in supplying human cellular models to pharma and biotech for preclinical research.

Broad incumbents

• Charles River Laboratories: Charles River is a major preclinical CRO offering safety pharmacology and toxicology services. It is a broad incumbent that competes with Tissue Dynamics for outsourced preclinical safety contracts and is increasingly building in vitro/organoid capabilities.
• Cyprotex (Evotec): Cyprotex, an Evotec company, provides ADME-Tox and organ-on-chip preclinical services. It is a broad incumbent in human-relevant in vitro toxicology, comparable to Tissue Dynamics' MechaniX-enabled safety pharmacology offering.

Others

• Galmed Pharmaceuticals: Galmed is an Aramchol-focused clinical-stage pharma partner of Tissue Dynamics. While not a competitor, it is a key commercial counterpart whose ongoing collaboration validates real-world demand for Tissue Dynamics' cardiac fibrosis platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tissue-dynamics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissue Dynamics